Clinical Trials Directory

Trials / Conditions / Severe Eosinophilic Asthma

Severe Eosinophilic Asthma

18 registered clinical trials studyying Severe Eosinophilic Asthma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in I
NCT07214753
AstraZeneca—
TerminatedClock Proteins as Prognostic Markers
NCT06302959
Medical University of Graz—
Active Not RecruitingSTEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic A
NCT06465485
AstraZenecaPhase 3
Active Not RecruitingMepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophil
NCT06069310
National and Kapodistrian University of Athens—
CompletedA Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma
NCT05440656
AstraZeneca—
CompletedReal World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
NCT05271526
AstraZeneca—
CompletedTreatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma
NCT05063981
Istituti Clinici Scientifici Maugeri SpA—
CompletedRANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
NCT05180357
AstraZeneca—
UnknownSevere Asthma, MepolizumaB and Affect: SAMBA Study
NCT04680611
University Hospital Southampton NHS Foundation Trust—
UnknownNon-coding RNAs Analysis of Eosinophil Subtypes in Asthma
NCT04542902
Lithuanian University of Health SciencesN/A
CompletedA Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Tre
NCT04159519
AstraZenecaPhase 4
CompletedStudy to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in
NCT04126499
AstraZeneca—
CompletedReal World Study With Benralizumab in Severe Asthma in Switzerland
NCT03907137
AstraZeneca—
CompletedPatient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
NCT03833141
AstraZeneca—
UnknownImpact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
NCT03652376
University of RostockPhase 4
UnknownA Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic A
NCT03739320
Sotiria General Hospital—
UnknownMepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
NCT04084613
Attikon Hospital—
CompletedEffect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
NCT02560610
Chiesi Farmaceutici S.p.A.Phase 2